Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study

References

• Amiot A, Peyrin-Biroulet L. Currrent, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases. Therap Adv Gastroenterol. 2015;8(2):66–82.
   PubMed Web of Science ®Google Scholar
• Magro F, Estevinho MM, Dias CC, et al. Clinical, endoscopic and histological outcomes in induction of moderate-to-severe ulcerative colitis: a systematic review with meta-analysis. J Crohns Colitis. 2021;15(4):551–566.
   PubMed Web of Science ®Google Scholar
• Ma C, Sedano R, Almradi A, et al. An international consensus to standardize integration of histopathology in ulcerative colitis clinical trials. Gastroenterology. 2021;160(7):2291–2302.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583.
   PubMed Web of Science ®Google Scholar
• Tadbiri S, Nachury M, Bouhnik Y, et al. The IBD-disk is a reliable tool to assess the daily-life burden of patients with inflammatory bowel disease. J Crohns Colitis. 2020;15(5):766–777.
   Web of Science ®Google Scholar
• Amiot A, Bouguen G, Bonnaud G, et al. Clinical guidelines for the management of inflammatory bowel disease: update of a French national consensus. Dig Liver Dis. 2021;53(1):35–43.
   PubMedGoogle Scholar
• D'Amico F, Fiorino G, Furfaro F, et al. Patient’s profiling for therapeutic management of inflammatory bowel disease: a tailored approach. Expert Rev Gastroenterol Hepatol. 2020;14(9):765–773.
   PubMed Web of Science ®Google Scholar
• Jairath V, Chan K, Lasch K, et al. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis. Expert Rev Gastroenterol Hepatol. 2021;15(6):711–722.
   PubMed Web of Science ®Google Scholar
• Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–1007; quiz e78.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Dignass A, Peyrin-Biroulet L, et al. Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease. J Gastroenterol. 2018;53(9):1048–1064.
   PubMed Web of Science ®Google Scholar
• Amiot A, Grimaud J-C, Peyrin-Biroulet L, et al. Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14(11):1593–1601.e2.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicenter cohort study. Aliment Pharmacol Ther. 2017;46(3):310–321.
   PubMed Web of Science ®Google Scholar
• Amiot A, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020;51(11):1039–1046.
   PubMed Web of Science ®Google Scholar
• Fumery M, Filippi J, Abitbol V. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944–951.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
   PubMed Web of Science ®Google Scholar
• Travis SPL, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145(5):987–995.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110(9):1324–1338.
   PubMed Web of Science ®Google Scholar
• Rosenbaum PR. Model-based direct adjustment. J Am Statist Assoc. 1987;82(398):387–394.
   Web of Science ®Google Scholar
• Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424.
   PubMed Web of Science ®Google Scholar
• Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–3679.
   PubMed Web of Science ®Google Scholar
• Xu S, Ross C, Raebel MA, et al. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health. 2010;13(2):273–277.
   PubMed Web of Science ®Google Scholar
• Austin PC. Variance estimation when using inverse probability of treatment weighting (IPTW) with survival analysis. Stat Med. 2016;35(30):5642–5655.
   PubMed Web of Science ®Google Scholar
• R Core Team. R: A language and environment for statistical ## computing. R Foundation for Statistical Computing, 2020.
   Google Scholar
• Singh S, Murad MH, Fumery M, et al. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. Clin Gastroenterol Hepatol. 2020;18(10):2179–2191.e6.
   PubMed Web of Science ®Google Scholar
• Bots S, Gecse K, Barclay M, et al. Combination immunosuppression in IBD. Inflamm Bowel Dis. 2018;24(3):539–545.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Ghosh S, Middleton S, et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology. 2014;146(2):392–400 e3.
   PubMed Web of Science ®Google Scholar
• Yzet C, Diouf M, Singh S, et al. No benefit of concomitant immunomodulator therapy on efficacy of biologics that are not tumor necrosis factor antagonists in patients with inflammatory bowel diseases: a meta-analysis. Clin Gastroenterol Hepatol. 2021;19(4):668–679.e8.
   PubMed Web of Science ®Google Scholar
• Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn’s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341–353.
   PubMed Web of Science ®Google Scholar
• Alric H, Amiot A, Kirchgesner J, et al. The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn’s disease refractory to anti-tumour necrosis factor. Aliment Pharmacol Ther. 2020;51(10):948–957.
   PubMed Web of Science ®Google Scholar
• Faleck DM, Shmidt E, Huang R, et al. Effect of concomitant therapy with steroids and tumor necrosis factor antagonists for induction of remission in patients with Crohn’s disease: a systematic review and pooled meta-analysis. Clin Gastroenterol Hepatol. 2021;19(2):238–245.e4.
   PubMed Web of Science ®Google Scholar
• Alric H, Amiot A, Kirchgesner J, et al. Vedolizumab clinical decision support tool predicts efficacy of vedolizumab but not ustekinumab in refractory Crohn’s disease. Inflamm Bowel Dis. 2022;28(2):218–225.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Amiot A, Peyrin-Biroulet L, et al. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn’s disease. Aliment Pharmacol Ther. 2020;51(5):553–564.
   PubMed Web of Science ®Google Scholar
• Sands BE, Peyrin-Biroulet L, Loftus EV, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214.
   PubMed Web of Science ®Google Scholar